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ABSTRACT 
Gastric cancer is still a major health problem worldwide due to its frequency, poor 
prognosis and limited treatment options. To study the inhibitory effect of nuclear 
transcription factor kappa B(NF-κB) antisense oligodeoxynucleotide(ASODN) on the 
growth and tumorgenesis of human gastric cancer, we synthesis and transfect ASODN 
of NF-κB/P65 to gastric cancer cell line. The effect of ASODN of NF-κB/P65 on the 
proliferation of gastric cancer cells was measured by MTT method. The subcutaneous 
xenograft model of human gastric cancer was established in nude mice and the tumor 
growth curve was observed. The cell proliferation was significantly inhibited in P65 
ASODN transfected group in vitro (P<0.05). In vivo, tumor formation test showed 
that the tumor volume in nude mice in ASODN group was obviously smaller than in 
other groups (P<0.05), the apoptosis index (AI) was significantly higher (P<0.001). 
Stimultaneously, MVD in ASODN group was markedly lower than in other groups 
(P<0.01). Our findings suggest that P65 ASODN can inhibit gastric cancer cells 
proliferation and tumorgenesis by inducing cell apoptosis and inhibiting tumor 
angiogenesis. NF-κB can be used as a new biological therapeutic target of gastric 
cancer. 
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INTRODUCTION 
 
 
NF-κB is activated by a variety of cancer-promoting agents[1]. Recent studies showed 
that as a multifunctional factor, NF-κB involved in a variety of physiological and 
pathological processes such as immunity,  inflammation, gene expression, cancer 
cell migration invasion, cell apoptosis and proliferation[2-6].The mechanism of NF-κB 
activation in tumor cells is not well elucidated, but it is apparently complex and varies 
in different tumor types[7]. NF-κB constitutive activation was identified in some 
cancer cells such as breast cancer, liver cancer, prostate cancer, pancreatic cancer, and 
gastric cancer[8]. Also, we have previously shown that there exists NF-κB constitutive 
activation in gastric cancer cell [9,10]. Antisense reagents and technology have 
developed as extraordinarily useful tools for analysis of gene function. The capacity 
of antisense to reduce expression of RNA has led to the concept of using antisense 
molecules as drugs to treat cancer. behalf of all your co-authors, you are prepared to 
accept this condition should your paper be published. You may also use this text box for any 
additional comments about your submission. (ASOs) inhibit translation or induce 
degradation of complementary target RNA, and both Phase I and Phase II trials such 
as antisense anti-IGF-I[11], antisense oligonucleotide GTI-2040[12], antisense 
oligonucleotide ISIS 5132[13] are either completed or in progress. ASOs have proved 
their efficacy as targeted therapy in preclinical studies, have been well tolerated and 
able to modulate target protein expression in clinical studies[14,15]. Here we examined 
the impact that antisense oligonucleotide NF-κB on cell proliferation and 
tumorgenesis of gastric cancer in nude mice. 
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MATERIALS AND METHODS 
Cell line and reagents  
SGC-7901 gastric cancer cell line was obtained from Committee on Type Culture 
Collection of Chinese Academy of Sciences(Shanghai, China). Cells were cultured in 
RPMI-1640 medium (Gibco BRL, Life Technologies Inc., USA) including 10% 
inactivated fetal bovine serum, 2mM L-glutamine, 100U/ml penicillin, and 100 U/ml 
streptomycin at 37 °C in a humidified atmosphere with 5% CO2.  
Synthesis of antisense oligonucleotide 
P65 antisense oligonucleotide and misantisense oligonucleotides (MSODN)sequence 
was from the literature[16]. Antisense sequence: 5’ GGG GAA CAG TTC GTC CAT 
GGC 3’, target sequence: 5’ GCC ATG GAC GAA CTG TTC CCC 3’, missense 
sequence: 5’ GTA CGC GGT GAA GCT GCG ATC 3’. According to Genbank, 
ASODN and MSODN do not match with any known gene. They were synthesized by 
Takara Biotechnology Co., Ltd (Dalian, China) with phosphorathioate oligonucleotide 
technology followed by HPLC purification. 
Transfection of human gastric cancer cell 
Cells would be 90% confluent at the time of transfection, the liposome was 
respectively mixed with antisense and missense oligonucleotides in serum-free 
medium in accordance with DOTAP Liposomal Transfection Reagent(Roche, Swiss) 
instructions to form liposome-oligonucleotide complexes, which were then added into 
culture plate. The final concentration of oligonucleotide was 160nmolL-1. 
Seventy-two hours after transfection, cells were harvested for Western Blot, cell 
immunofluorescence. 
MTT examination 
The cell proliferating activity was measured by MTT method. During logarithmic 
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growth phase, cells were digested by 0.05% trypsin containing 0.02% EDTA. Cells 
were seeded in 96-well plates at a density of 4,000 cells/well and there were triplicate 
wells in each experimental and control group. After cells transfected by P65 ASODN, 
MSODN, liposome and incubate for 24h, 48h, 72h and 96 hours, 20μl MTT (Sigma, 
USA) at a final concentration of 5 mg/ml was placed in each well, and incubated for 4 
hours at 37°C. The reaction was stopped by adding 100 μl DMSO(Sigma, USA), and 
the absorbance was measured at 490 nm in a microplate reader (μQuant, Bio-Tek, 
Instruments, Inc. UAS). After treatment, cells were treated with MTT (5 mg/ml) and 
incubated for 4 h at 37 °C.  
Preparation of nuclear extracts 
After transfection, cells were washed with cold phosphate buffered saline (PBS), 
harvested, and pelleted, then resuspended in buffer A (10mM Hepes, pH 7.9, 10mM 
KCL, 0.6% Nonidet P-40, 1mM EDTA, 1mM PMSF and 1mM DTT) and incubated 
on ice for 15 minutes. After centrifugation at 14000 rpm for 15 minutes, the 
supernatant cytoplasmic protein was collected. The remnants were resuspended in 
buffer B (20mM Hepes, pH 7.9, 400mM KCL, 20% glycerol, 1mM EDTA, 1mM 
PMSF and 1mM DTT) and incubated on ice for 30 minutes, and stirred 
discontinuously every 10 minutes, then centrifugated at 14000 rpm for 15 minutes, the 
supernatant nuclear extract was collected. All proteins were stored at -80℃. Protein 
concentration was determined by BCA kit (Pierce Biotechnology Inc, USA). 
SDS-PAGE and Western blot analysis 
The nuclear extracts were boiled for 10 min, resolved by SDS-PAGE on an 10% 
polyacrylamide gel, and blotted onto nitrocellulose membrane.The membranes were 
incubated in blocking solution (5% non-fat dry milk in 20 mM Tris-HCl 150 mM 
NaCl and 0.1% Tween-20). After washing with TBS, membranes were incubated by 
primary antibodies solution (p65 monoclonal antibodies, Santa Cruz, USA, 1:500) for 
3 hours at room temperature. Membranes were washed and incubated by the goat 
anti-mouse secondary antibody conjugated to alkaline phosphatase (1:1000, Santa 
Cruz, USA) for 1 hour. Then the membranes were then incubated with 
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HRP-conjugated secondary antibodies and visualized by ECL Plus system 
(Amersham Life Sciences, Piscataway, NJ). The difference of NF-κB expression was 
judged according to the brightness of lanes. 
Nude mouse gastric cancer models 
BALB/c nude mice (4weeks old) were purchased from Shanghai Laboratory Animal 
Center(Shanghai, China). Mice were kept in a pathogen-free environment. The 
different cells transfected by P65 ASODN, liposome and P65 MSODN were 
trypsinized, washed twice with DMEM and resuspended in 0.1 ml PBS for 
transplantation in nude mice. 2×106 cells were injected into nude mice subcutaneously. 
The date on which the first grossly visible tumor appeared for subcutaneous injection 
was recorded, and the tumor size was measured every 3 days. Two-dimensional 
measurements were taken with an electronic caliper after injection, and tumor volume 
was calculated. Tumor volume was calculated by the following formula: volume 
(mm3) =a2*b/2, where a is the width in mm and b is the length in mm. Mice were 
sacrificed and dissected 4 weeks after cell inoculation.  
Apoptosis detection by TUNEL assay 
The reagent kit for apoptosis detection, TdT-FragEL DNA fragmentation detection kit 
was bought from ONCOGENE. Test procedures consisting of the following sections 
were provided in the brochure of the kit. Tumor tissues were fixed in 4% 
formaldehyde, dehydrated with gradient ethanol, and embedded in paraffin. 
Paraffin-embedded tissue samples were cut at 4 μm and examined on a coated slide 
glass. The specimens were deparaffinized and hydrated gradually, and rinsed with 
1×TBS, then incubated with proteinase K (20g/mL in 10 mmol/L Tris-HCl) for 20 
min. After immersed in 30 mL/L H2O2 at room temperature for 5 min and in TdT 
labeling reaction mixture at 37℃  for 1.5 h, specimens were covered with 
1×conjugate for 30 min, visualized by DAB and counterstained by hematoxylin. TBS 
took the place of primary antibodies as a negative control. After being mounted, 
sections were observed under microscope. The results of staining were analyzed and 
evaluated with American Image-Pro Plus software. The percentage of positive cells 
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with TUNEL staining in five 400×sights served as apoptosis index (AI). 
HE staining and MVD detection 
MVD was detected by HE staining and counted according to Weidner method. Areas 
of highest neovascularization were found by scanning the tumor sections at low power 
(×100 total magnification).After the area of highest neovascularization was identified, 
individual microvessel counts were made on a ×200 field. Any highlighted 
endothelial cell or endothelial cell cluster clearly separate from adjacent microvessels, 
tumor cells, and other connective tissue elements was considered a single, countable 
microvessel.  
 
Statistical analysis 
The Statistical Package for the Social Science (SPSS) for Microsoft Windows 11.0 
was used to complete the analysis of the collected data. All data were expressed as 
means ± SEM. The means of the different groups were compared using one-way 
analysis of variance (ANOVA) test. Significant differences were accepted when 
P<0.05.  
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RESULTS 
 
ASODN inhibits P65 expression  
To determine the effect of ASODN on expression of P65 in gastric cancer cells, we 
transfected SGC-7901 gastric cancer cells with P65 ASODN. Simultaneously, P65 
MSODN as a control. We observed the protein expression of p65 by Western blot 
analysis. The results showed that the expression of P65 was lower in the ASODN 
groups than the control groups (P<0.001, Fig 1). There is no difference among the 
control groups.  
P65 ASODN inhibits SGC-7901 gastric cancer cell growth 
MTT assay was performed at different time period (at 24, 48, 72, 96hrs) after 
transfection. Decreased cell survival rate was observed in the ASODN group(P65 
ASODN working concentration is 0.4μmol/l). The inhibition rates ranged from 
30.06% to 45.12%, and the results are shown in Figure In the other groups, 
cells’viability is well. There was statistically significant difference in P65 ASODN 
group when compared to control group(P<0.05, Fig2). The difference was not 
statistically significant among the other groups. There is no time-dependent difference 
in four groups. 
P65 ASODN suppresses gastric tumor growth in vivo 
Because it showed that P65 ASODN has a significant inhibitory effect on the growth 
of gastric cancer cells in vitro, we next studied the effect of ASODN on tumor growth 
in vivo. For this, we injected gastric cancer cell transfected by P65 ASODN into nude 
mice. We periodically monitored the growth of tumor for 24 days. In the P65 ASODN 
group, the tumor volume is smaller than that in P65 MSODN-treated mice as reflected 
in Fig. 3 and Tab1. (P<0.05 at day 9, 12, 15, 18, 24, 21 and 24, respectively). To 
evaluate a potential toxicity of liposome vector, we found the tumor volume were 
similar in liposome and the control group without transfection of liposome vector 
(P>0.05), indicating that liposome does not have notable toxicity to mice. 
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P65 ASODN reduce the microvessel density(MVD) and induce apoptosis in vivo 
At the endpoint, mice were sacrificed and examined for angiogensis in tumor by 
MVD analysis and cell apoptosis by TUNEL. MVD in the P65 ASODN group was 
reduced significantly (Fig. 4A, left panels). The ASODN group had a mean MVD of 
3.8±0.8, while MVD in control, liposome, MSODN group was 7.4±1.5, 6.8±0.8, 
6.4±1.1 microvessels respectively. There was statistically significant difference 
between ASODN group and the other groups(P<0.01). The difference among 
MSODN, liposome and control group had no statistically significance(P>0.05). P65 
ASODN suppresses the gastric tumor growth, it maybe related to reducing 
angiogenesis. For induction of apoptosis in the xenograft model, TUNEL-positive 
cells were distinguished by brown-stained nuclei (Figure 4B, right panels). The 
number of apoptotic cells in P65 ASODN groups had increased. The mean AI in 
ASODN group was 21.67±2.52%, AI in control, liposome, MSODN group was 
15.33±0.58%, 7.33±1.53%, 9.0±1.73% respectively. The apoptosis index of the P65 
ASODN group were significantly higher than that in the control groups (P<0.001). It 
showed P65 ASODN maybe induce gastric cancer cells apoptosis in vivo. These 
results strongly indicate that the inhibition of P65 ASODN induced cell apoptosis and 
eventually led to tumor growth suppression, which is consistent with our in vitro data. 
 
 
 
 
 
,  
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DISCUSSION 
In 1986, Baltimore first discovered transcription factor nuclear (NF-κB) in mature B 
cell nucleus[17]. It was one of the nuclear proteins, which bind with DNA enhancer of 
immunoglobulin κ light chain. In mammalian cells, it was a kind of dimeric protein 
complex, composed of homodimers and heterodimers derived from five distinct 
subunits, including NF-κB1 (p50), NF-κB2 (p52), RelA (p65), Rel B, and c-Rel. P65 
contains transcription activating area, and participates in original regulation of gene 
transcription. Simultaneously, p65 facilitates the combination of p50 with DNA. All 
family members share a highly conserved Rel homology domain (RHD, ~300aa) 
responsible for DNA binding, dimerization domain, and interaction with IκBs, the 
intracellular inhibitor of NF-κB[18,19]. In most quiescent normal cells, the majority of 
NF-κB complexes are kept predominantly as an inactive form cytoplasmic and in an 
inactive form by binding to a family of inhibitory proteins, the IκBs. Many divergent 
extracellular stimuli including proinflammatory cytokines such as TNF-α, 
interleukin-1, lipopolysaccharide (LPS), double-stranded RNA, and physical and 
chemical stresses can induce rapid phosphorylation and degradation of IκB, allowing 
nuclear translocation of NF-κB[20]. This process is called activation of NF-κB. The 
signaling pathways involved in NF-κB constitutive activation remain largely 
unknown. Mechanism of constitutive activation of NF-κB may be involved in 
activation of tyrosine kinase, NIK, and IKK[21]. NF-κB is involved in cancer 
development, modulating NF-κB activation pathways has important implications in 
cancer prevention and therapy. Due to the complexity of NF-κB roles in different 
cancers, careful evaluation of NF-κB in each cancer type is crucial in this regard. 
More cancer cell-specific NF-κB inhibiting means are desired for improving 
anticancer efficacy and reducing systemic toxicity. In this study, it was suggested that 
P65 ASODN could inhibit gastric cancer cell proliferation, it maybe related to the 
decreased expression of P65. Many cell cyclin gene expression is 
NF-κB-dependent[22]. The best explored link between NF-κB activation and cell cycle 
 10 / 22 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
10
.5
26
2.
1 
: P
os
te
d 
15
 N
ov
 2
01
0
progression involves cyclin D1, a cyclin which is expressed relatively early in the cell 
cycle and which is crucial to commitment to DNA synthesis. Experiments in many 
cell types now indicate that NF-κB acts through increasing the abundance of cyclin 
D1 and thus the activity of the cyclin D1 kinase holoenzyme complex. The role of 
NF-κB factors in controlling the cell cycle and cyclin D1 has been well shown in 
investigations that used the IκB “super repressor” (IκB-SR), to inhibit NF-κB activity. 
IκB-SR effectively blocks the serum-induced increase in nuclear NF-κB DNA 
binding activity in mouse embryo fibroblasts and delays S-phase entry when the cells 
are growing synchronously[23]. The regulator of cell-cycle progression cyclin D1 is 
upregulated in a variety of cancer cells by mechanisms involving mainly 
transcriptional activation. Analysis of the human cyclin D1 promoterhas revealed the 
presence of two κB sites located at -840 and -33, designated κB1 and κB2, 
respectively, and mutational analysis demonstrated that p50/p65 binding to the -33 
κB2 site was important for cyclin D1 transcriptional regulation during proliferation 
induced by serum or growth factors[24].  
And also in vivo, we found P65 ASODN inhibited tumor growth which lead to 
apoptosis increasing and angiogensis reducing. In vitro and in vivo, both liposome 
only and MSODN can also inhibited gastric cancer cells proliferation and inhibited 
tumorgenesis, which related to slight toxicity of liposome, there is no statistic 
difference. It was well known that tumor angiogenesis is dependent on many 
proinflammatory cytokines and growth factors such as IL-8, TNF-α and VEGF. 
NF-κB plays a pivotal role in secreting the angiogenesis factors[25,26]. Constitutive 
NF-κB activation in cancer cells also triggers autocrine of angiogenic chemokines, 
and NF-κB inhibition substantially suppresses tumor growth and angiogenesis[27]. 
Previously, there reported NF-κB-mediated IL-8 and angiogenin expression was 
involved in this process[28]. In this experiment, we noticed that P65 ASODN as 
inhibitor of NF-κB leads to an decrease in tumor angiogenesis in nude mice. 
The evidence that cancer development is a complex and multistep process, 
characterized by alterations of genes involved in the regulation of proliferation, 
apoptosis and angiogenesis, has led to development of new therapeutic strategies 
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based on the use of agents able to selectively inhibit key molecules of these pathways. 
Although these agents have shown considerable promise for antitumoral therapy, 
treatment with ASODN used as single agent does not seem particularly promising 
because of the multigenic alterations of tumors. 
Transcription factors have potential as targets for an individualized therapeutic 
approach to cancer[29]. Hopefully, in the next few years several NF-κB inhibitors that 
can increase the therapeutic efficiency of chemotherapy and radiotherapy will be 
successfully employed in treatment of gastric cancer patients. 
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FIGURE LEGENDS 
 
Fig 1. Changes in the expression of P65 in gastric cancer cells treated after 
transfecting ODN.  
A. Western blot analysis of P65 expression. Scans of original blots with GAPDH used 
as loading controls. A representative blot is shown from three independent 
experiments with identical observations. B. The expression of P65 was significant 
lower in the P65 ASODN transfected group when compared to control, liposome and 
MSODN group(P<0.001).  
 
Fig2. Inhibitory effects of P65 ASODN on SGC-7901 gastric cancer cell growth 
examined by MTT assay.  
A．The cell proliferating activity on 24, 48, 72 and 96h in the experimental group was 
significant inhibited when compared to control, MSODN, liposome group（P<0.01）. 
The data are represented as mean±standard deviation. B. Green fluorescent in gastric 
cancer cells after transfection with P65 ASODN. Photograph show that P65 ASODN 
was tansfected into cancer cell. 
 
Fig3. Comparsion of tumor size among different groups and tumor growth curve 
in nude mice. 
A. All mice were monitored for survival for 24 days. At 24th day, mice were killed 
and tumors were removed. Representative photographs show tumor size in different 
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groups. B. Tumor volume curve. Tumor volume (mm3) was also measured by external 
calipers twice per week and calculated as described under Materials and methods. 
Each point represents the mean for n=15 animals. The results represent the 
mean±standard deviation. The experiment was repeated independently at least three 
times with similar results. Significant inhibition in MSODN group versus in other 
groups at the termination of the experiment(P<0.05). 
 
Fig4. Comparison of MVD and AI in nude mice.  
A. Blood vessel morphology in tumor xenografts(×200). Blood vessels were stained 
by HE staining in light microscopy at 200×magnification. Arrows show blood vessel. 
Tumors characterized by large and thick, singly distributed vessels, often with a 
visible lumen were assigned as large vessels, while tumors characterized by small and 
thin vessels forming networks without a visible lumen were assigned as small vessels. 
The mean MVD were 7.4±1.5, 6.8±0.8, 6.4±1.1, 3.8±0.8 in control, liposome, 
MSODN and ASODN group respectively. B. Detection of apoptotic cells in tumor 
tissue by TUNEL assay(×200). Arrows show TUNEL-positive cells. The mean 
apoptosis index were 15.33±0.58%, 7.33±1.53%, 9.0±1.73%, 21.67±2.52% 
respectively. C. Histograms show AI in different groups. There was statistically 
significant difference between ASODN group and the other groups(P<0.001). D. 
Histograms show MVD in different groups. There was statistically significant 
difference between ASODN group and the other groups(P<0.01).  
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 TABLE 
 
 
 
Tab1. The tumor volume in different groups and in different time 
Tumor volume（mm3, X±SD）  
Groups 
9d 12d 15d 18d 21d 24d P value
control(A) 69±52 150±112 369±291 776±353 930±448 1048±486  
liposome(B) 75±60 207±124 382±221 709±320 841±337 1067±350  
MSODN (C) ** 52±32 102±56 252±170 625±163 776±175 911±229 >0.05 
ASODN (D)* 27±24 61±54 171±118 265±213 334±247 382±270 <0.05 
* The tumor volume in group D is smaller than the other groups(P<0.05). 
** There is no difference among tumor volume in group C and A, B(P>0.05). 
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